134 related articles for article (PubMed ID: 26774656)
1. Gene silencing using a conjugate comprising Tat peptide and antisense oligonucleotide with phosphorothioate backbones.
Maegawa Y; Mochizuki S; Miyamoto N; Sakurai K
Bioorg Med Chem Lett; 2016 Feb; 26(4):1276-8. PubMed ID: 26774656
[TBL] [Abstract][Full Text] [Related]
2. Double-clicking peptides onto phosphorothioate oligonucleotides: combining two proapoptotic agents in one molecule.
Abendroth F; Seitz O
Angew Chem Int Ed Engl; 2014 Sep; 53(39):10504-9. PubMed ID: 25138283
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, cellular uptake and HIV-1 Tat-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptides.
Turner JJ; Arzumanov AA; Gait MJ
Nucleic Acids Res; 2005; 33(1):27-42. PubMed ID: 15640444
[TBL] [Abstract][Full Text] [Related]
4. A DNA uptake-stimulating protein increases the antiproliferative effect of c-myb antisense oligonucleotide on leukemic cells.
Tóth G; Schlammadinger J; Aradi J; Antal-Szalmás P; Sipka S; Balázs M; Kovács P; Fehér Z; Falus A
Cell Biol Int; 2004; 28(11):817-23. PubMed ID: 15563404
[TBL] [Abstract][Full Text] [Related]
5. 3'-methylphosphonate-modified oligo-2'-O-methylribonucleotides and their Tat peptide conjugates: uptake and stability in mouse fibroblasts in culture.
Prater CE; Miller PS
Bioconjug Chem; 2004; 15(3):498-507. PubMed ID: 15149177
[TBL] [Abstract][Full Text] [Related]
6. HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers.
Moulton HM; Hase MC; Smith KM; Iversen PL
Antisense Nucleic Acid Drug Dev; 2003 Feb; 13(1):31-43. PubMed ID: 12691534
[TBL] [Abstract][Full Text] [Related]
7. Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates.
Astriab-Fisher A; Sergueev DS; Fisher M; Shaw BR; Juliano RL
Biochem Pharmacol; 2000 Jul; 60(1):83-90. PubMed ID: 10807948
[TBL] [Abstract][Full Text] [Related]
8. Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions.
Astriab-Fisher A; Sergueev D; Fisher M; Shaw BR; Juliano RL
Pharm Res; 2002 Jun; 19(6):744-54. PubMed ID: 12134943
[TBL] [Abstract][Full Text] [Related]
9. Conjugation of peptides to antisense interleukin-6 via click chemistry.
Wang CF; Auriola S; Hirvonen J; Santos HA
Curr Med Chem; 2014 Apr; 21(10):1247-54. PubMed ID: 24251570
[TBL] [Abstract][Full Text] [Related]
10. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.
Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S
J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
13. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
[TBL] [Abstract][Full Text] [Related]
14. [Antisense oligonucleotides with antitumor activity].
Otvös L; Sági G
Magy Onkol; 2004; 48(3):221-7. PubMed ID: 15520872
[TBL] [Abstract][Full Text] [Related]
15. Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation.
Steinhauser IM; Langer K; Strebhardt KM; Spänkuch B
Biomaterials; 2008 Oct; 29(29):4022-8. PubMed ID: 18653231
[TBL] [Abstract][Full Text] [Related]
16. High Boron-loaded DNA-Oligomers as Potential Boron Neutron Capture Therapy and Antisense Oligonucleotide Dual-Action Anticancer Agents.
Kaniowski D; Ebenryter-Olbińska K; Sobczak M; Wojtczak B; Janczak S; Leśnikowski ZJ; Nawrot B
Molecules; 2017 Aug; 22(9):. PubMed ID: 28832537
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
[TBL] [Abstract][Full Text] [Related]
18. Stepwise synthesis of oligonucleotide-peptide conjugates containing guanidinium and lipophilic groups in their 3'-termini.
Grijalvo S; Terrazas M; Aviñó A; Eritja R
Bioorg Med Chem Lett; 2010 Apr; 20(7):2144-7. PubMed ID: 20206515
[TBL] [Abstract][Full Text] [Related]
19. Antisense Oligonucleotides Internally Labeled with Peptides Show Improved Target Recognition and Stability to Enzymatic Degradation.
Taskova M; Madsen CS; Jensen KJ; Hansen LH; Vester B; Astakhova K
Bioconjug Chem; 2017 Mar; 28(3):768-774. PubMed ID: 28292178
[TBL] [Abstract][Full Text] [Related]
20. Grafting multi-maleimides on antisense oligonucleotide to enhance its cellular uptake and gene silencing capability.
Guo Y; Zhang J; Pan G; Choi CHJ; Wang P; Li Y; Zhu X; Zhang C
Chem Commun (Camb); 2020 Jul; 56(54):7439-7442. PubMed ID: 32494799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
